
| Disease Domain | Count | 
|---|---|
| Nervous System Diseases | 8 | 
| Neoplasms | 2 | 
| Endocrinology and Metabolic Disease | 2 | 
| Infectious Diseases | 1 | 
| Top 5 Drug Type | Count | 
|---|---|
| Small molecule drug | 10 | 
| Chemical drugs | 1 | 
| Microbiota | 1 | 
| Synthetic peptide | 1 | 
| Colony-stimulating factors | 1 | 
| Target | 
| Mechanism EPO receptor agonists [+1]  | 
| Active Org. | 
| Originator Org. | 
| Active Indication | 
| Inactive Indication- | 
| Drug Highest PhasePhase 2 | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target | 
| Mechanism CD82 inhibitors | 
| Active Org. | 
| Originator Org. | 
| Active Indication | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target- | 
| Mechanism Cell replacements | 
| Active Org. | 
| Originator Org. | 
| Active Indication | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Start Date01 Oct 2025 | 
| Sponsor / Collaborator  Hanyang University  [+1]  | 
| Start Date28 May 2025 | 
| Sponsor / Collaborator  [+5]  | 
| Start Date12 May 2025 | 
| Sponsor / Collaborator | 

| Drug(Targets) | Indications | Global Highest Phase | 
|---|---|---|
| Recombinant human erythropoietin(Hanyang University)(  EPO receptor ) | Amyotrophic Lateral Sclerosis More | Phase 2 | 
| rCT-S100A8/A9(  MOK x TLR4 ) | Colorectal Cancer More | Preclinical | 
| Mesenchymal stem cell therapy  (Hanyang University/SCM Lifescience) | Diabetic Foot More | Preclinical | 
| Compound 32e(Hanyang University)(  CCNK x CDK12 ) | HER2 Positive Breast Cancer More | Preclinical | 
| Compound 22b(Hanyang University)(  JNK3 ) | Alzheimer Disease More | Preclinical | 





